title: Spectral domain optical coherence tomographic analysis of healthy retina in branch retinal vein occlusion and its response to antiangiogenic therapy.
abstract: OBJECTIVE
  To propose a model that measures the effect of intravitreal bevacizumab (IVB) on relatively healthy retina. The purpose is to analyze the remote effect of a branch retinal vein occlusion in the healthy retina, to determine the response it may have to IVB, and to determine if IVB has an atrophic effect on the healthy retina.
  
  
  METHODS
  Retrospective, longitudinal comparative analysis of patients with branch retinal vein occlusion treated with IVB. Eyes were divided into experimental (branch retinal vein occlusion eye) and control (contralateral eye) groups. Each eye was analyzed for thickness and area. Thickness measurements were performed for total retinal thickness, inner retina thickness, and outer retina thickness. Area was measured for photoreceptors, choroid, and total retina.
  
  
  RESULTS
  Eighteen eyes of 9 patients. For thickness analysis, 1,050 scans were studied, and 126 measurements were performed on 42 scans for area analysis. No difference was observed for thickness, except for inner retina thickness. No difference was observed for area. No difference was observed when analyzing a cumulative exposure to IVB.
  
  
  CONCLUSIONS
  There is no evidence to suggest an atrophic effect caused by IVB when analyzing thickness or area in this experiment. This model could be used to analyze the long-term safety of IVB in larger studies.
authors.affiliation: *Department of Ophthalmology, University of Colorado School of Medicine, Denver Health Medical Center, Denver, Colorado; and †Rocky Mountains Lions Eye Institute, University of Colorado School of Medicine, Aurora, Colorado.
authors.forename: Guillermo
authors.initials: G
authors.lastname: Salcedo-Villanueva
authors.forename: Mariana
authors.initials: M
authors.lastname: Harasawa
authors.forename: Raul
authors.initials: R
authors.lastname: Velez-Montoya
authors.forename: Marc T
authors.initials: MT
authors.lastname: Mathias
authors.forename: Frank S
authors.initials: FS
authors.lastname: Siringo
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Olson
authors.forename: Scott C
authors.initials: SC
authors.lastname: Oliver
authors.forename: Naresh
authors.initials: N
authors.lastname: Mandava
authors.forename: Hugo
authors.initials: H
authors.lastname: Quiroz-Mercado
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001284:Atrophy; D000068258:Bevacizumab; D002829:Choroid / Q000187:drug effects / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D012160:Retina / Q000187:drug effects* / Q000473:pathology; D012170:Retinal Vein Occlusion / Q000188:drug therapy* / Q000503:physiopathology; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab